Peptide Initiative

Dosing protocol · Healing & Recovery

ARA-290 (Cibinetide) dosing & administration

A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain

Suggested dose

1 – 8 mg

Once dailyFrequency
SubcutaneousRoute
Ongoing/indefiniteCycle length

Dosing

How much ARA-290 (Cibinetide) do I take?

Subcutaneous

Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.

Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.

3 documented dose levels — separate regimens, not a titration schedule

  • 1 mg

    Frequency
    Once daily
    Duration
    28 days

    Lowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds .

  • 4 mg

    Frequency
    Once daily
    Duration
    28 days

    The 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose .

  • 8 mg

    Frequency
    Once daily
    Duration
    28 days

    Highest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes .

Intravenous

Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.

Bioavailability Complete (about 100%) — delivered straight into the bloodstream.

  • 2 mg

    Frequency
    Three times weekly
    Duration
    4 weeks

    An earlier sarcoidosis pilot gave 2 mg into a vein three times a week and saw improved nerve symptoms .

Timing

Best time to take

Administer ARA-290 (Cibinetide) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.

With food?

ARA-290 (Cibinetide) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.

If stacking

ARA-290 (Cibinetide) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting your dose

Increase if

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Decrease if

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

Signs of right dose

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Administration

How do I use ARA-290 (Cibinetide)?

Reconstitution

What you need

  • ARA-290 (Cibinetide) vial (lyophilized powder or solution)
  • Bacteriostatic water or sterile sodium chloride for reconstitution
  • Alcohol swabs for cleaning vial tops and injection sites
  • Appropriately sized syringes with fine-gauge needles (27-30 gauge)
  • Sharps disposal container

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

Storage

Before reconstitution

Store ARA-290 (Cibinetide) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, ARA-290 (Cibinetide) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation — discard the vial

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Sample daily schedule

  • As prescribed (once daily)

    As prescribed by your healthcare provider injection

    Site: Subcutaneous injection—rotate sites if applicable

    Maintain a consistent schedule for optimal results with ARA-290 (Cibinetide). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is ARA-290 (Cibinetide) safe?

Side effects

Commonly reported: Injection Site Reactions, Headache, Dizziness

Less common: Elevated Blood Pressure, Fatigue

Serious side effects

  • Blood Clot Formation

Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with ARA-290 (Cibinetide)
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

ARA-290 (Cibinetide) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Flagged pairings

  • Erythropoietin (EPO) — Both activate similar pathways; combining could cause excessive red blood cell production
  • Uncontrolled antihypertensive medications — May cause dangerous blood pressure fluctuations
  • Anticoagulants at high doses — May increase thrombosis risk

Published research

What the studies show

  • Moderate human trials (Phase 1-2)
  • Not FDA approved
  1. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

    Brines M, et al. · 2015PubMed

    ARA-290 treatment resulted in significant improvement of neuropathic pain in diabetic patients along with increased corneal nerve fibers. The peptide showed disease-modifying properties with long-lasting beneficial effects on both pain-related and non-pain-related symptoms.

  2. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain

    Culver DA, et al. · 2017PubMed

    Cibinetide at 4 mg daily significantly increased corneal nerve fiber area by 697 μm², along with increased regenerating intraepidermal fibers. Pain improved significantly in all groups, with changes in nerve fiber abundance correlating with improvements in walking distance and pain severity.

  3. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy

    Brines M, et al. · 2018PubMed

    Corneal nerve fiber area measurements proved useful for tracking therapeutic response to ARA-290 treatment in neuropathy. The metric showed quantifiable changes in nerve morphology and provided superior sensitivity to identify nerve repair compared to skin biopsy.

  4. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection

    Liu Y, et al. · 2014PubMed

    ARA 290 greatly improved recovery from autoimmune nerve inflammation by promoting nerve regeneration and remyelination while suppressing inflammation. The treatment increased protective regulatory T cells and reduced pro-inflammatory immune responses.

  5. ARA 290 for treatment of small fiber neuropathy in sarcoidosis

    van Velzen M, et al. · 2014PubMed

    ARA 290 treatment was associated with significant improvements in neuropathic pain, increased corneal nerve fibers, improved sensory thresholds, and better quality of life in sarcoidosis patients. The excellent safety profile combined with disease-modifying properties makes it promising for treating this orphan disease.

  6. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

    Heij L, Niesters M, Swartjes M, et al. · 2012PubMed

    Intravenous ARA 290 at 2 mg three times weekly for 4 weeks improved small fiber neuropathy symptoms versus placebo in sarcoidosis patients.

Head to head

ARA-290 (Cibinetide) compared

Want the full picture?

The complete ARA-290 (Cibinetide) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.